Triflusal

Summary

Triflusal (CHEMBL1332032) is a phase-3 clinical-stage small molecule (ATC B01AC18); indicated across 2 conditions including thrombotic disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: B01AC18
• Indications: 2 conditions
• Clinical trials: 6
• Chemistry: 248.15 Da · C10H7F3O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1332032
Name	Triflusal
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	9458
ATC	B01AC18
Molecular formula	C10H7F3O4
Molecular weight	248.15
InChIKey	RMWVZGDJPAKBDE-UHFFFAOYSA-N

SMILES: CC(=O)OC1=C(C=CC(=C1)C(F)(F)F)C(=O)O

IUPAC name: 2-acetyloxy-4-(trifluoromethyl)benzoic acid

Also known as: Triflusal, SID11112328, SID144203987, TRIFLUSAL, triflusal

Patent coverage: 836 distinct patent families (3,038 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 3,027 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Lysine-specific demethylase 4E, Ubiquitin carboxyl-terminal hydrolase 2, 15-hydroxyprostaglandin dehydrogenase [NAD(+)], Aldehyde dehydrogenase 1A1, Cytochrome P450 2C19, 3-hydroxyacyl-CoA dehydrogenase type-2.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 7 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CYP2C19	5.4	Potency	3981	nM	CHEMBL_ACT_4019292
CYP2C19	5.4	AC50	3981	nM	CHEMBL_ACT_6064736
USP2	5.3	Potency	5012	nM	CHEMBL_ACT_4719762

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
thrombotic disease	3	MONDO:0000831	HP:0004419

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE4	3
PHASE2	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01174693	PHASE4	COMPLETED	Comparison of Triflusal and Clopidogrel in Secondary Prevention of Stroke Based on the Genotyping
NCT01612273	PHASE4	COMPLETED	The Effect of Triflusal on Peripheral Microcirculation Dysfunction
NCT02616497	PHASE4	COMPLETED	ASpirin vs Triflusal for Event Reduction In Atherothrombosis Secondary Prevention (ASTERIAS)
NCT00162799	PHASE2	COMPLETED	Efficacy Pilot Study of Triflusal in the Attenuation of Insulin Resistance in Human Obesity
NCT02321852	PHASE2	COMPLETED	Influence of Triflusal on Cognitive Functions in Healthy Subjects
NCT02904109	PHASE2	COMPLETED	Influence of Triflusal on Cognitive Functions in Subjects Under Chronic Stress

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).